← Human Trials & Peer-Reviewed Studies
Effect of intracanal medicaments on matrix metalloproteinase-9 and vasoactive intestinal peptide secretion in periapical lesions of re-treated canals: a randomized controlled clinical study
Plain-language guide to PMID 29948282 (2019): randomized controlled trial study of VIP (Vasoactive Intestinal Peptide) in 60 patients.
Key Facts
- PMID
- 29948282
- Journal
- Clinical oral investigations
- Year
- 2019
- Study type
- Randomized Controlled Trial
- Authors
- Özdemir MB et al. (4 authors)
- DOI
- 10.1007/s00784-018-2517-8
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at VIP (Vasoactive Intestinal Peptide).
The aim of this study was to evaluate the effect of calcium hydroxide (Ca[OH]2) and chlorhexidine (CHX) gel on matrix metalloproteinase-9 (MMP-9) and vasoactive intestinal peptide (VIP) secretion in periapical lesions.
Why It Was Studied
VIP is a neuropeptide that promotes new bone formation.
Thus, intracanal Ca(OH)2 medication may accelerate the repair process of bone tissue.
Who Took Part
According to the abstract, 60 patients were involved.
The age groups tagged for this paper are adults, both men and women.
A total of 60 patients were randomly divided into two groups that were to receive different medications.
Pre-and post-treatment samples were collected from the interstitial fluid of periapical lesions using sterile paper points.
How the Study Was Run
The design is described as randomized.
Random assignment meant chance, not the researchers, decided who got VIP (Vasoactive Intestinal Peptide) and who got the comparison, which limits bias.
VIP and MMP-9 levels were measured by enzyme-linked immunosorbent assay kits, and the data were statistically analyzed.
What Was Measured
Topics PubMed links to this paper include Calcium Hydroxide, Chlorhexidine, Enzyme-Linked Immunosorbent Assay, Matrix Metalloproteinase 9, Periapical Periodontitis, Retreatment and Root Canal Irrigants.
The authors tagged it with the keywords CHX gel, Ca(OH)2, Matrix metalloproteinase-9 and Vasoactive intestinal peptide.
What This Means in Plain Language
The paper is a randomized study of VIP (Vasoactive Intestinal Peptide) in 60 patients.
Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2019 (Clinical oral investigations), a journal based in Germany.
More context: the VIP (Vasoactive Intestinal Peptide) compound page, all human trials.
Our Notes on the Compound
VIP (Vasoactive Intestinal Peptide): A 28-amino-acid neuropeptide that relaxes smooth muscle and calms immune activity; aviptadil is a synthetic form.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.